Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Medtronic PLC Stock Research

MDT

80.46USD-0.33(-0.41%)Market Closed
Watchlist

Market Summary

USD80.46-0.33
Market Closed
-0.41%

MDT Alerts

  • 1 major insider sales recently.

MDT Stock Price

MDT RSI Chart

MDT Valuation

Market Cap

107.1B

Price/Earnings (Trailing)

29.52

Price/Sales (Trailing)

3.39

EV/EBITDA

14.73

Price/Free Cashflow

24.09

MDT Price/Sales (Trailing)

MDT Profitability

EBT Margin

17.18%

Return on Equity

7.27%

Return on Assets

4.13%

Free Cashflow Yield

4.15%

MDT Fundamentals

MDT Revenue

Revenue (TTM)

31.6B

Revenue Y/Y

4.49%

Revenue Q/Q

-9.87%

MDT Earnings

Earnings (TTM)

3.6B

Earnings Y/Y

-14.85%

Earnings Q/Q

-32.91%

Price Action

52 Week Range

75.1092.02
(Low)(High)

Last 7 days

-1.8%

Last 30 days

-3.9%

Last 90 days

-8.0%

Trailing 12 Months

-5.4%

MDT Financial Health

Current Ratio

2.39

Debt/Equity

0.47

Debt/Cashflow

0.25

MDT Investor Care

Dividend Yield

3.4%

Dividend/Share (TTM)

2.73

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

2.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for MDT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-23
Smith Gregory L
sold
-838,400
83.84
-10,000
evp global ops & supply chain
2023-08-14
Wall Brett A.
sold
-83,380
83.38
-1,000
evp & pres neuroscience
2023-08-04
Marinaro Michael
sold
-113,717
84.11
-1,352
evp & president, surgical ou
2023-08-03
Salmon Sean
acquired
-
-
5,604
evp & president cardiovascular
2023-08-03
Marinaro Michael
acquired
-
-
1,696
evp & president, surgical ou
2023-08-03
Marinaro Michael
sold (taxes)
-111,780
84.49
-1,323
evp & president, surgical ou
2023-08-03
TEN HOEDT ROB
acquired
-
-
4,251
evp and pres. global regions
2023-08-03
WHITE ROBERT JOHN
sold (taxes)
-343,452
84.49
-4,065
evp & pres. medical surgical
2023-08-03
Wall Brett A.
acquired
-
-
5,168
evp & pres neuroscience
2023-08-03
PARKHILL KAREN L
acquired
-
-
7,105
evp & chief financial officer

1–10 of 50

Which funds bought or sold MDT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
added
0.96
86,341
921,967
0.78%
2023-09-14
Proquility Private Wealth Partners, LLC
added
0.18
315,910
3,648,440
1.43%
2023-09-13
CGC Financial Services, LLC
new
-
41,759
41,759
0.03%
2023-09-12
DCM Advisors, LLC
unchanged
-
74,964
882,938
0.38%
2023-09-12
Farther Finance Advisors, LLC
added
35.86
116,457
356,765
0.08%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
reduced
-3.74
1,678
34,007
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
2,710,570
2,710,570
0.14%
2023-09-05
Covenant Partners, LLC
added
30.58
117,402
392,397
0.14%
2023-09-05
Westshore Wealth, LLC
reduced
-2.5
14,332
233,377
0.12%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
2,321
27,336
0.04%

1–10 of 47

Latest Funds Activity

Are funds buying MDT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDT
No. of Funds

Schedule 13G FIlings of Medtronic

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2023
blackrock inc.
9.2%
122,349,678
SC 13G/A
Feb 09, 2023
vanguard group inc
9.41%
125,126,702
SC 13G/A
Feb 01, 2022
blackrock inc.
8.0%
107,903,361
SC 13G/A
Feb 10, 2021
vanguard group inc
8.27%
111,286,018
SC 13G/A
Feb 03, 2021
wellington management group llp
2.87%
38,648,749
SC 13G/A
Jan 29, 2021
blackrock inc.
7.96%
107,107,760
SC 13G/A
Feb 12, 2020
vanguard group inc
8.55%
114,617,479
SC 13G/A
Feb 05, 2020
blackrock inc.
8.2%
109,561,921
SC 13G/A
Jan 27, 2020
wellington management group llp
5.13%
68,769,139
SC 13G/A

Recent SEC filings of Medtronic

View All Filings
Date Filed Form Type Document
Sep 13, 2023
ARS
ARS
Aug 31, 2023
10-Q
Quarterly Report
Aug 31, 2023
IRANNOTICE
IRANNOTICE
Aug 25, 2023
4
Insider Trading
Aug 23, 2023
144
Notice of Insider Sale Intent
Aug 22, 2023
8-K
Current Report
Aug 16, 2023
4
Insider Trading
Aug 14, 2023
144
Notice of Insider Sale Intent
Aug 11, 2023
DEFA14A
DEFA14A
Aug 11, 2023
DEF 14A
DEF 14A

Peers (Alternatives to Medtronic)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
107.1B
31.6B
-3.89% -5.40%
29.52
3.39
1.57% -30.40%
99.9B
6.7B
-0.98% 45.79%
70.1
14.99
11.75% -0.66%
42.7B
5.7B
-7.62% -17.65%
30.7
7.54
5.64% -4.53%
23.0B
3.7B
-14.60% 32.47%
73.17
6.15
-6.33% -49.26%
17.3B
4.0B
-8.83% 11.42%
35.74
4.28
-22.73% -67.98%
MID-CAP
9.6B
937.8M
-0.82% 34.59%
329.38
10.23
16.30% 250.21%
4.5B
2.6B
-15.10% -17.76%
20.82
1.75
1.78% -15.77%
3.1B
1.1B
-4.32% 17.29%
35.22
2.73
9.28% 177.49%
3.0B
1.1B
0.89% 9.63%
-30.91
2.77
6.60% -233.50%
1.9B
151.1M
-13.07% 24.15%
-104.73
12.31
193.70% 62.80%
SMALL-CAP
1.2B
177.1M
-13.07% -17.06%
-20.42
7.02
23.02% 15.37%
941.3M
780.7M
-8.43% -11.84%
-26.15
1.21
4.68% -510.17%
550.8M
162.2M
12.61% -45.53%
-6.55
3.4
9.71% 12.37%
119.4M
349.3M
-18.77% -79.39%
-1.24
0.34
-1.13% -239.54%
53.9M
414.9M
-23.07% -60.47%
-0.65
0.13
-23.37% 16.91%

Medtronic News

MarketWatch
Medtronic PLC stock outperforms competitors despite losses on the day.
MarketWatch,
9 hours ago
The Motley Fool
Investor's Business Daily
Baystreet.ca
Orchestra, Medtronic Join Forces.
Baystreet.ca,
2 days ago
Finbold - Finance in Bold

Returns for MDT

Cumulative Returns on MDT

6.1%


10-Year Cumulative Returns

0.7%


7-Year Cumulative Returns

-2.1%


5-Year Cumulative Returns

-7.0%


3-Year Cumulative Returns

Risks for MDT

What is the probability of a big loss on MDT?

53.9%


Probability that Medtronic stock will be more than 20% underwater in next one year

32.7%


Probability that Medtronic stock will be more than 30% underwater in next one year.

0%


Probability that Medtronic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MDT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Medtronic was unfortunately bought at previous high price.

Drawdowns

Financials for Medtronic

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue1.1%31,55931,22730,77230,80831,07031,68631,78531,79731,59730,11727,92727,86927,92828,91431,06230,89130,66630,55730,55530,37829,947
  S&GA Expenses0.4%10,46110,41510,36810,31410,31210,29210,31810,29410,27910,1489,9139,9639,98310,10910,37010,37910,36410,41810,39410,32110,255
EBITDA-100.0%-8,6978,7148,8919,0128,7778,7368,3797,7407,5226,1706,5276,9917,8109,448------
EBITDA Margin-100.0%-0.28*0.28*0.29*0.29*0.28*0.27*0.26*0.24*0.25*0.22*0.23*0.25*0.27*0.30*------
Interest Expenses-2.5%6206365925625805535525588929259469596541,0921,6481,7351,8111,4441,0431,0701,102
Earnings Before Taxes2.9%5,5175,3645,4165,6305,7285,5175,4815,1124,1443,8952,5342,8933,6624,0555,1424,9334,9945,1975,6305,2875,660
EBT Margin-100.0%-0.17*0.18*0.18*0.18*0.17*0.17*0.16*0.13*0.13*0.09*0.10*0.13*0.14*0.17*------
Net Income-3.5%3,6273,7584,0714,3295,2115,0394,9264,7163,8933,6062,9013,5464,4234,8095,3354,6894,4334,6314,9192,2613,163
Net Income Margin-100.0%-0.12*0.13*0.14*0.17*0.16*0.15*0.15*0.12*0.12*0.10*0.13*0.16*0.17*0.17*------
Free Cashflow-100.0%-4,5804,1664,8225,7215,9785,6785,7735,8554,8854,6314,7524,7566,0216,659------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.2%90,77690,94894,13493,24189,91490,98191,80491,75691,80293,08397,27095,88693,90690,68992,82291,05391,26889,69488,73088,15089,721
  Current Assets0.9%21,86921,67525,36425,39822,13523,05923,30322,73122,43422,54826,34726,03624,50922,03124,04322,65322,70521,96720,87721,65322,460
    Cash Equivalents-13.2%1,3391,5434,5214,8282,1403,7143,4792,9003,0043,5935,0776,4206,4994,1403,7093,9625,0804,3933,7033,9114,380
  Inventory7.1%5,6685,2935,3755,0554,8094,6164,5144,3494,2884,3134,5084,4844,5514,2294,1224,0423,9323,7533,8663,7633,681
  Net PPE1.7%5,6655,5695,4375,2985,2815,4135,2515,1885,1625,2215,0234,9384,8824,8284,7644,7564,7114,6754,5934,5364,524
  Goodwill0.0%41,43641,42541,56540,41766.0061580.0080.0041,72041,96180538140,71439,84192.0092.0065.0039,95914660.0062.00
Liabilities0.3%39,41039,28342,51641,18437,07138,26039,09139,59640,13741,48146,34245,57043,46339,81740,86940,33440,77139,48238,78938,43639,392
  Current Liabilities0.0%9,0479,05114,42214,46514,04912,3948,9277,8037,7648,50912,53412,07113,08610,3668,7358,1708,5188,4728,8538,4639,112
  Long Term Debt0.5%24,46324,34422,21020,75317,48120,37224,29025,60725,95826,37826,50225,96722,86722,02124,73224,75224,80424,48623,67423,67323,678
Shareholder's Equity-0.6%51,17851,48351,44152,05752,84352,72252,71352,15951,66451,60250,92850,31650,44350,87251,95350,71950,49750,21249,94149,71450,329
  Retained Earnings-0.4%30,26530,39230,11729,79930,27630,25029,60728,97428,51128,59428,01527,52627,81728,13228,21027,01826,37726,27025,76925,17124,730
  Additional Paid-In Capital0.0%24,58724,59024,51324,44224,33524,56625,81426,05926,18426,31926,66526,48126,26126,16526,14426,17126,47026,53226,51827,04827,817
Accumulated Depreciation---8,4898,1998,0437,9527,8237,7907,6467,4797,3757,2607,0706,8166,7436,6086,4256,2456,1535,9765,812
Shares Outstanding0.0%1,3301,3311,3301,3301,3291,3311,3441,3451,3451,3451,3461,3441,3421,3411,3411,3411,3411,3411,3431,3491,353
Minority Interest3.3%188182177177170171171168178174170152147135145141134121112107105
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-3.4%5,8316,0395,6366,2907,1377,3467,0347,1627,2546,2405,9455,9966,0027,2347,8717,5196,8157,0075,9585,9055,649
  Share Based Compensation3.1%366355352349352359356343343344337338306297297291287290302314316
Cashflow From Investing29.9%-2,447-3,493-2,747-2,897-2,460-1,659-11.00-2,347-3,658-2,866-4,420-3,448-2,644-3,203-4,097-3,305-1,968-774-1344976,418
Cashflow From Financing9.1%-4,511-4,960-2,019-1,062-5,231-5,336-8,516-8,337-7,150-4,136-317-192-1,965-4,198-3,748-4,143-4,132-5,431-8,399-7,980-12,386
  Dividend Payments0.4%3,6313,6163,5543,4973,4403,3833,3213,2553,1883,1203,0633,0052,9482,8942,8412,7892,7402,6932,6462,5982,546
  Buy Backs-38.4%3976451,8902,1992,4722,5441,6161,2539636521954229061,3261,2651,7012,3202,8772,8702,2741,758

MDT Income Statement

2023-07-28
Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Jul. 28, 2023
Jul. 29, 2022
Income Statement [Abstract]  
Net sales$ 7,702$ 7,371
Costs and expenses:  
Cost of products sold, excluding amortization of intangible assets2,6282,516
Research and development expense668692
Selling, general, and administrative expense2,6132,567
Amortization of intangible assets429423
Restructuring charges, net5414
Certain litigation charges400
Other operating expense, net135
Operating profit1,2681,125
Other non-operating income, net(76)(83)
Interest expense, net148164
Income before income taxes1,1961,044
Income tax provision400112
Net income797931
Net income attributable to noncontrolling interests(6)(2)
Net income attributable to Medtronic$ 791$ 929
Basic earnings per share (usd per share)$ 0.59$ 0.70
Diluted earnings per share (usd per share)$ 0.59$ 0.70
Basic weighted average shares outstanding (shares)1,330.51,329.4
Diluted weighted average shares outstanding (shares)1,333.81,334.5

MDT Balance Sheet

2023-07-28
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jul. 28, 2023
Apr. 28, 2023
Current assets:  
Cash and cash equivalents$ 1,339$ 1,543
Investments6,5376,416
Accounts receivable, less allowances and credit losses of $190 and $176, respectively5,8065,998
Inventories, net5,6685,293
Other current assets2,5182,425
Total current assets21,86921,675
Property, plant, and equipment, net5,6655,569
Goodwill41,43641,425
Other intangible assets, net14,43414,844
Tax assets3,4613,477
Other assets3,9123,959
Total assets90,77690,948
Current liabilities:  
Current debt obligations51920
Accounts payable2,2392,662
Accrued compensation1,6951,949
Accrued income taxes1,013840
Other accrued expenses3,5813,581
Total current liabilities9,0479,051
Long-term debt24,46324,344
Accrued compensation and retirement benefits1,0921,093
Accrued income taxes2,4072,360
Deferred tax liabilities687708
Other liabilities1,7151,727
Total liabilities39,41039,283
Commitments and contingencies (Note 16)
Shareholders’ equity:  
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,498,304 and 1,330,809,036 shares issued and outstanding, respectively00
Additional paid-in capital24,58724,590
Retained earnings30,26530,392
Accumulated other comprehensive loss(3,674)(3,499)
Total shareholders’ equity51,17851,483
Noncontrolling interests188182
Total equity51,36651,665
Total liabilities and equity$ 90,776$ 90,948
Geoffrey S. Martha
65535
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.